Revance Therapeutics — Technical Presentation (October 2015)
18 slides from Revance Therapeutics's technical presentation, Oct 29, 2015
Slide 1: BELMONT Phase 2 Active Comparator Trial 24-Week Topline Interim Results
BELMONT Phase 2 Active Comparator Trial 24-Week Topline Interim Results DAN BROWNE President & CEO OCTOBER 29, 2015 Exhibit 99.1
Slide 2: Forward-Looking Statements/Safe Harbor
Forward-Looking Statements/Safe Harbor This presentation contains forward-looking statements, including statements relating to: our RT002 investigational drug product candidate, including but not limited to statements about the current and potential features and benefits, the process and timing of a
Slide 3: BELMONT 24-Week Results Positive: Efficacy & Safety Highlights
BELMONT 24-Week Results Positive Planning to Accelerate RT002 Injectable into Phase 3 in 2H 2016 Confidential and Proprietary *BOTOX® (VISTABEL® in Canada) are registered trademarks of Allergan, Inc. Efficacy & Safety Highlights: As measured by investigators, all three RT002 doses achieved 100% one-
Slide 4: BELMONT 24-Week Results Positive: Duration Highlights
BELMONT 24-Week Results Positive Planning to Accelerate RT002 Injectable into Phase 3 in 2H 2016 Confidential and Proprietary Duration Highlights: Achieved 6-month duration of effect with high responder rates Statistically superior duration to VISTABEL/BOTOX Cosmetic 6-month median duration of at le
Slide 5: BELMONT Study Design
BELMONT Study Design A Phase 2, Randomized, Double-Blind, Dose Ranging, Active and Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy and Duration of Effect of RT002, a Botulinum Toxin Type A for Injection, to Treat Glabellar Lines Confidential and Proprietary Protocol Title
Slide 6: BELMONT Study Assessments
BELMONT Study Assessments Efficacy evaluations versus baseline Every 4 weeks for up to 36 weeks using Investigator Global Assessment-Facial Wrinkle Severity (IGA-FWS) All subjects were followed for at least 24 weeks Primary Efficacy Assessments ≥ 1-point improvement IGA-FWS Duration of response Risk
Slide 7: Key Efficacy, Safety and Duration Data
Key Efficacy, Safety and Duration Data BELMONT 24-Week Interim Results
Slide 8: 100% Response Rates For All RT002 Doses
100% Response Rates For All RT002 Doses Placebo N=35 BOTOX N=34 RT002 20U N=39 RT002 40U N=41 RT002 60U N=42 ≥ 1 pt 3% 95% 100% 100% 100% ≥ 2 pt 0% 76% 74% 85% 95%* None or Mild 0% 93% 97% 97% 98% Confidential and Proprietary * Statistically significant vs. BOTOX Cosmetic. Study not powered for stat
Slide 9: Summary of Safety (Safety Population)
Summary of Safety (Safety Population) All five groups exhibited an excellent overall safety profile in interim data No serious adverse events Adverse events were predominantly localized, transient and mild in severity and typically injection related (erythema and pain) Most common adverse events by
Slide 10: Duration of Effect Separates RT002 from BOTOX
Duration of Effect Separates RT002 from BOTOX Kaplan-Meier Curve: Duration of Response for at least a 1-point improvement from Baseline for IGA-FWS Assessment (Per-Protocol Population) *BOTOX® (VISTABEL® in Canada) are registered trademarks of Allergan, Inc.
Slide 11: RT002 40U Outperforms BOTOX At All Time Points
RT002 40U showed higher response rate for None or Mild wrinkles by Investigator Assessment at all time points RT002 40U Outperforms BOTOX At All Time Points Dose Group Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 40U 97% 97%* 85% 67%* 46%* 31%* BOTOX 93% 83% 69% 32% 22% 12% * Statistically signific
Slide 12: Example 1-Point Improvement by IGA-FWS
Pre-treatment Week 24 RT002 40 U MAXIMUM FROWN Example 1-Point Improvement by IGA-FWS Photo ID RT002 2801
Slide 13: Example 1-Point Improvement by IGA-FWS & PFWS
Pre-treatment Week 24 RT002 40 U MAXIMUM FROWN Example 1-Point Improvement by IGA-FWS & PFWS Photo ID RT002 2802
Slide 14: Example 1-Point Improvement by IGA-FWS & PFWS
Pre-treatment Week 24 RT002 20 U MAXIMUM FROWN Photo ID RT002 2803 Example 1-Point Improvement by IGA-FWS & PFWS
Slide 15: Conclusions From Topline Interim Analysis
Conclusions From Topline Interim Analysis Confidential and Proprietary RT002 achieves statistically significant 6-month duration of effect with higher responder rates compared to BOTOX RT002 40U appears well-tolerated with no ptosis. Efficacy was statistically superior at the majority of time points
Slide 16: BELMONT Subject Rating of Duration Importance
BELMONT Subject Rating of Duration Importance Study included subject questionnaire to determine attitudes around duration of effect: 87% said duration was Somewhat Important, Important or Very Important 79% said duration was Important or Very Important More than half (51%) rated duration the Very Im
Slide 17: Planned Next Steps for RT002 in Glabellar Lines
Planned Next Steps for RT002 in Glabellar Lines Plan to complete study and report final results 1H 2016 Expect to complete End-of-Phase 2 meeting with FDA 1H 2016 Anticipate initiating Phase 3 pivotal studies 2H 2016
Slide 18: Transforming the Neurotoxin Market
Transforming the Neurotoxin Market
Revance Therapeutics — Technical Presentation (October 2015) on 6ix